- Sunshine Biopharma Inc. raises $2.46 million via a direct offering.
- Analysts predict significant upside potential, with a target price of $300.
- GF Value estimation suggests substantial growth opportunity.
Sunshine Biopharma Inc. (SBFM, Financial) has successfully completed a registered direct offering, securing approximately $2.46 million. This capital was raised through the sale of common stock and pre-funded warrants at a price of $2.07 per share. The proceeds are earmarked for fulfilling the company’s general corporate needs and enhancing its working capital. Aegis Capital Corp. served as the exclusive placement agent for this offering.
Analyst Forecasts and Ratings
According to projections from a single analyst, Sunshine Biopharma Inc. (SBFM, Financial) boasts a one-year average target price of $300.00. This figure represents both the high and low estimate provided, highlighting a remarkable potential upside of 21,302.58% from its current trading price of $1.40. For more in-depth forecast information, please visit the Sunshine Biopharma Inc (SBFM) Forecast page.
The consensus recommendation from one brokerage firm paints a promising picture for SBFM, with an average brokerage recommendation score of 2.0. This score signifies an "Outperform" status on a scale where 1.0 equals a "Strong Buy" and 5.0 equals a "Sell".
Analysis from GuruFocus
GuruFocus estimates the GF Value of Sunshine Biopharma Inc. (SBFM, Financial) at $236.50 in one year, indicating a prospective upside of 16,772.37% from the current price of $1.4017. The GF Value is GuruFocus' calculated assessment of the stock's fair value, based on historical trading multiples, previous business growth, and anticipated future performance. For further elaboration on these calculations, investors should consult the Sunshine Biopharma Inc (SBFM) Summary page.
